Imagine a cunning disguise so effective that it fools your body’s own defense system into letting a deadly enemy thrive. That’s exactly what pancreatic cancer does, and it’s one of the reasons this disease remains so notoriously hard to treat. But groundbreaking research from Northwestern University has just pulled back the curtain on this devious tactic, revealing a new target that could revolutionize immunotherapy. And this is the part most people miss: pancreatic cancer cells cloak themselves in a specific sugar molecule, sialic acid, to trick the immune system into thinking they’re harmless.
In a study published in Cancer Research (https://aacrjournals.org/cancerres/article-abstract/doi/10.1158/0008-5472.CAN-25-0977/767104/Targeting-Interactions-Between-Siglec-10-and-3-1?redirectedFrom=fulltext), Dr. Mohamed Abdel-Mohsen and his team uncovered how pancreatic tumor cells exploit this sugar shield to evade immune attack. It took them six years to crack this code, but the discovery is a game-changer. “Pancreatic cancer essentially disguises itself in sugar,” Abdel-Mohsen explains. “This sugar sends a message to the immune system: ‘Don’t attack me—I’m one of you.’ It’s like a wolf in sheep’s clothing, but on a microscopic scale.”
But here’s where it gets controversial: Could this sugar-based deception be a common tactic across other hard-to-treat cancers? Abdel-Mohsen believes so, and his findings suggest that targeting this mechanism could open new doors for immunotherapy, not just for pancreatic cancer but for other “cold” tumors like glioblastoma.
Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is one of the deadliest cancers, with a five-year survival rate below 13%. Its immunosuppressive environment is a major hurdle, preventing immune cells from recognizing and destroying tumor cells. Abdel-Mohsen’s study identifies a key player in this puzzle: PDAC cells are coated with sialic acid sugars attached to a protein called integrin α3β1. These sugars bind to Siglec-10, a receptor on immune cells, which acts as a ‘glyco-immune checkpoint,’ effectively telling the immune system to stand down.
“When Siglec-10 binds to sialic acid, it’s like a ‘ceasefire’ signal for immune cells,” Abdel-Mohsen clarifies. “The macrophages, which should be devouring cancer cells, are instead left inactive, allowing the tumor to grow unchecked.”
What’s fascinating—and surprising—is how pancreatic cancer differs from other cancers like breast and ovarian tumors, which use a similar sugar-based mechanism but with a different ligand, CD24. PDAC cells, however, rely on integrin α3β1 as their Siglec-10 binding partner. This highlights the adaptability of cancer in outsmarting the immune system. “We were stunned to find that the same immune receptor, Siglec-10, is hijacked by a completely different molecule in pancreatic cancer,” Abdel-Mohsen notes. “It’s a testament to cancer’s ingenuity in evading detection.”
To counter this, Abdel-Mohsen’s team developed an antibody that blocks Siglec-10, preventing it from binding to the sialic-acid-coated integrin. This reactivates macrophages, enabling them to attack tumor cells directly and ‘educate’ T cells to join the fight. In lab experiments, this antibody alone reduced pancreatic tumor growth in mice by 36–40%. Combining it with existing immunotherapies, like PD-1 or PD-L1 inhibitors, could create a powerful dual attack on cancer.
“Current immunotherapies focus on T cells, but if the macrophages—the teachers of the immune system—are inactive, T cells can’t learn to fight the tumor,” Abdel-Mohsen explains. “Our approach wakes up the teachers, while other drugs activate the students. Together, they can mount a much stronger defense.”
The implications extend far beyond pancreatic cancer. Many cancers and even virally infected cells use similar sugar disguises to evade the immune system. This underscores the importance of glycobiology, the study of cell-surface sugars, in understanding immune regulation. “Glycobiology is still an underappreciated field,” Abdel-Mohsen points out. “Yet these sugar interactions are critical in determining what the immune system attacks or ignores. Ignoring them has limited our ability to combat immune evasion.”
Abdel-Mohsen and his team are now working with clinicians at Northwestern’s Lurie Cancer Center to move their findings into clinical trials. “We’re ensuring the antibody is safe and effective,” he says. “Our ultimate goal is to combine it with chemotherapy or existing immunotherapies for a comprehensive treatment approach.”
He stresses that pancreatic cancer won’t be defeated by a single therapy. “There’s no magic bullet,” Abdel-Mohsen admits. “It will take an arsenal of solutions working in tandem to outsmart the tumor.”
Here’s a thought-provoking question for you: If targeting sugar-based immune checkpoints like Siglec-10 proves successful, could this be the breakthrough needed to bring immunotherapy to cancers that have long resisted it? Share your thoughts in the comments—let’s spark a discussion on the future of cancer treatment!
